CC-5013 (Lenalidomide)

Katalognr.S1029 Batch:S102907

Skriv ut

Tekniska data

Formel

C13H13N3O3

Molekylvikt 259.26 CAS-nr. 191732-72-6
Löslighet (25°C)* In vitro DMSO 51 mg/mL (196.71 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Tillsätt lösningsmedel till produkten individuellt och i ordning.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validerad av Selleck-laboratorier. Om du behöver justeringar av denna formulering, kontakta vårt säljteam för skräddarsydd testning.

10.000mg/ml (38.57mM) Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml betyder svårlösligt eller olösligt.
* Vänligen notera att Selleck testar lösligheten för alla förbindelser internt, och den faktiska lösligheten kan skilja sig något från publicerade värden. Detta är normalt och beror på små variationer mellan olika partier.
* Rumstempererad frakt (Stabilitetstester visar att denna produkt kan fraktas utan några kylåtgärder.)

Beredning av stamlösningar

Biologisk aktivitet

Beskrivning Lenalidomid är en TNF-α sekretionshämmare med IC50 på 13 nM i PBMC:er. Lenalidomid (CC-5013) är en ligand till ubiquitin E3-ligas cereblon (CRBN), och det orsakar selektiv ubiquitinering och nedbrytning av två lymfoida transkriptionsfaktorer, IKZF1 och IKZF3, av CRBN-CRL4 ubiquitinligaset. Lenalidomid främjar klyvt Caspase-3 uttryck och hämmar VEGF uttryck och inducerar apoptos.
Mål
CRBN VEGF TNF-α
(PBMCs)
13 nM
In vitro

Lenalidomide strongly induces IL-2 and sIL-2R production. This compound-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB.

This compound and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for this compound resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and this chemical, CRBN protein is undetectable.

This chemical prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. It prevents induction of tumor-induced T cell lytic synapse dysfunction. This compound treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. This treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or this chemical treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with this agent reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking.

In Vivo

The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. This compound significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). It significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). This chemical significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM.

Protokoll (från referens)

Kinasanalys:

[1]

  • Analys för hämning av TNF-syntes av humana PBMC:er

    Humana PBMC:er från normala donatorer erhålls genom Ficoll−Hypaque densitetscentrifugering. Celler (106 celler/mL) odlas i RPMI kompletterat med 10 AB+ serum, 2 mM l-glutamin, 100 U/mL penicillin och 100 μg/mL streptomycin. Lenalidomid löses i DMSO vid 20 mg/mL; ytterligare utspädning görs med odlingsmedium. Den slutliga DMSO-koncentrationen i alla analyser inklusive kontrollerna är 0,25%. Denna förening tillsätts till celler 1 timme före tillsatsen av LPS. PBMC:er (106 celler/mL) stimuleras med 1 μg/mL LPS från Salmonella minnesota R595. Celler, i tre exemplar, inkuberas med LPS i 18–20 timmar vid 37 °C i 5% CO2. Supernatanterna skördas sedan och analyseras för cytokinnivåer. I vissa experiment hålls supernatanterna frysta vid –70 °C tills användning. Cellviabilitet analyseras med Trypan blue exklusionsfärgningsmetoden. Koncentrationen av TNFα i kultur supernatanterna bestäms med ELISA. Denna kemikalie analyseras i minst tre separata experiment. Procentuell hämning bestäms som 100 × [1 − (cytokin(experimentell)/cytokin(kontroll))].

Djurstudie:

[5]

  • Djurmodeller

    Adult male Sprague-Dawley rats bearing HUVECs cells

  • Doseringar

    50 mg/kg and 250 mg/kg

  • Administrering

    Administered via i.p.

Referenser

  • https://pubmed.ncbi.nlm.nih.gov/10386948/
  • https://pubmed.ncbi.nlm.nih.gov/16255679/
  • https://pubmed.ncbi.nlm.nih.gov/22552008/
  • https://pubmed.ncbi.nlm.nih.gov/22547582/
  • https://pubmed.ncbi.nlm.nih.gov/15797261/
  • https://pubmed.ncbi.nlm.nih.gov/21968939/
  • https://pubmed.ncbi.nlm.nih.gov/19951978/
  • http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50171
  • http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/1942?rss=1

Kundvalidering av produkt

<p> </p><p>Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α.</p>

Data från [ Obesity , 2012 , 20, 2174-85 ]

<p>MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure. B) MM.1S cells were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 4 hours. Whole lysates were immunoblotted with indicated antibodies</p><div><div> </div></div><p> </p>

, , Harvard Medical School

<p>MM.1S cells were cultured for 48 hours in the presence or absence of BMSCs with control media, AT9283, lenalidomide or  AT9283 plus lenalidomide. Cell proliferation was assessed by 3H-TdR uptake (left). MM.1S cells were cultured in the absence or presence of BMSCs and treated for 4 hours with drugs alone or in combination. Whole lysates were immunoblotted with indicated antibodies.</p><div><div> </div></div><p> </p>

, , Harvard Medical School

MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure.

Data från [ , , Clin Cancer Res, 2011, 17(10): 3259–71 ]

Sellecks CC-5013 (Lenalidomide) Har citerats av 190 Publikationer

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma [ Signal Transduct Target Ther, 2025, 10(1):29] PubMed: 39828715
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies [ Nat Commun, 2025, 16(1):3800] PubMed: 40268897
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities [ Cell Rep Med, 2025, S2666-3791(25)00102-8] PubMed: 40147445
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm [ Leukemia, 2025, 39(4):917-928] PubMed: 40000845
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect [ Cancer Research, 2025, 1978-1996] PubMed: 40163352
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect [ Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136] PubMed: 40163352
Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy [ Biomed Pharmacother, 2025, 184:117878] PubMed: 39891948
Rapid and high-throughput screening of proteolysis targeting chimeras using a dual-reporter system expressing fluorescence protein and luciferase [ BMC Biol, 2025, 23(1):51] PubMed: 39985000
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas [ Cancers (Basel), 2025, 17(12)2034] PubMed: 40563683
Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation [ Sci Rep, 2025, 15(1):12955] PubMed: 40234645

RETURPOLICY
Selleck Chemicals villkorslösa returpolicy säkerställer en smidig online-shoppingupplevelse för våra kunder. Om du på något sätt är missnöjd med ditt köp kan du returnera artikeln/artiklarna inom 7 dagar efter mottagandet. I händelse av produktkvalitetsproblem, antingen protokollrelaterade eller produktrelaterade problem, kan du returnera artikeln/artiklarna inom 365 dagar från det ursprungliga köpdatumet. Vänligen följ instruktionerna nedan vid retur av produkter.

FRAKT OCH FÖRVARING
Sellecks produkter transporteras i rumstemperatur. Om du tar emot produkten i rumstemperatur kan du vara trygg; Sellecks kvalitetskontrollavdelning har utfört experiment för att verifiera att placering i normal temperatur under en månad inte påverkar den biologiska aktiviteten hos pulverprodukter. Efter insamling ska produkten förvaras i enlighet med de krav som beskrivs i databladet. De flesta av Sellecks produkter är stabila under de rekommenderade förhållandena.

EJ AVSEDD FÖR ANVÄNDNING PÅ MÄNNISKOR, INOM VETERINÄRDIAGNOSTIK ELLER FÖR TERAPEUTISKT BRUK.